"Bortezomib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.
| Descriptor ID |
D000069286
|
| MeSH Number(s) |
D01.029.260.110.500 D01.132.285.500 D02.203.200.500 D03.383.679.450
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bortezomib".
Below are MeSH descriptors whose meaning is more specific than "Bortezomib".
This graph shows the total number of publications written about "Bortezomib" by people in this website by year, and whether "Bortezomib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 10 | 10 |
| 2004 | 0 | 12 | 12 |
| 2005 | 0 | 17 | 17 |
| 2006 | 0 | 23 | 23 |
| 2007 | 0 | 15 | 15 |
| 2008 | 0 | 11 | 11 |
| 2009 | 0 | 12 | 12 |
| 2010 | 0 | 15 | 15 |
| 2011 | 0 | 23 | 23 |
| 2012 | 0 | 20 | 20 |
| 2013 | 0 | 18 | 18 |
| 2014 | 1 | 19 | 20 |
| 2015 | 3 | 19 | 22 |
| 2016 | 5 | 4 | 9 |
| 2017 | 7 | 5 | 12 |
| 2018 | 3 | 7 | 10 |
| 2019 | 3 | 6 | 9 |
| 2020 | 5 | 6 | 11 |
| 2021 | 2 | 7 | 9 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 6 | 6 |
| 2024 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bortezomib" by people in Profiles.
-
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 07 08; 14(1):107.
-
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Oct 31; 391(17):1597-1609.
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
-
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 05 16; 143(20):2053-2058.
-
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 07; 99(7):1257-1268.
-
More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]. Blood Adv. 2023 10 24; 7(20):6275-6284.
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstr?m's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060.
-
Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. Proteomics Clin Appl. 2023 Nov; 17(6):e2200109.
-
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Rev. 2023 09; 61:101100.